First-in-human assessment of S-1117 in healthy volunteers
Official title: A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Single and Multiple Ascending Dose Trial of S-1117 in Healthy Volunteers
Run by Seismic Therapeutic AU Pty Ltd · NCT06828393 · Data updated 2026-11-12
This study is testing a new drug called S-1117 in healthy adults to see how safe it is and how it works in the body.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 96 (estimated) |
| Sponsor | Seismic Therapeutic AU Pty Ltd Industry-sponsored |
| Locations | 1 site (Adelaide, South Australia) |
| Status | Recruiting |
| Started | March 2025 |
| Main results expected | March 2026 |
| Study ends | March 2026 |
| Registry record updated | March 12, 2025 |
| Trial ID | NCT06828393 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are healthy adults aged 18 to 65 with a BMI between 18 and 32 kg/m2.
✕Probably not a fit
Patients with a history of severe allergies, immunodeficiency disorders, or certain medical conditions may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the safety, tolerability, pharmacokinetics, and pharmacodynamics of S-1117 in healthy adult participants. It is a randomized, placebo-controlled, double-blind trial conducted in two parts: the first part involves single ascending doses, while the second part focuses on multiple ascending doses. The goal is to gather essential data on how S-1117 behaves in the human body and its potential effects.
Why it matters
Potential benefit: If successful, this study could provide critical safety and efficacy data that may lead to the development of new therapeutic options.
How similar studies have gone: Other first-in-human studies have shown success in assessing new compounds, making this approach a standard practice in drug development.
Who can join: the full rules
Show full inclusion / exclusion criteria
Major Inclusion Criteria: 1. Is available for the entire duration of the study and follow up. 2. Is willing and able to comply with all study assessments and adhere to the protocol schedule and restrictions. 3. Voluntarily consents to participation in the trial as documented by signing the study informed consent form (ICF). 4. Has a body mass index (BMI) within 18 to 32 kg/m2, inclusive, and weighs ≥45 kg. 5. Is in good physical and mental health in the opinion of the Investigator or delegate. Major Exclusion Criteria: 1. Has a history of severe allergic or anaphylactic reaction as determined by the Investigator or delegate. 2. Is pregnant, nursing, or is planning to become pregnant or breastfeed during the trial. 3. Has a known immunodeficiency disorder. 4. Has a history of malignancy other than non-melanoma skin cancer. 5. Has a history of human immunodeficiency virus (HIV) or positive serology for HIV at Screening. 6. Has positive laboratory evidence for active hepatitis at screening. 7. Has received a live vaccine within 2 months of Screening. 8. Has any other condition or prior therapy that, in the opinion of the Investigator or delegate, may potentially compromise the safety or compliance of the participant, or may preclude the participant from successfully completing the study. Other inclusion/exclusion eligibility criteria apply.
Where it's running
-
CMAX Clinical Research
Adelaide, South Australia, Australia Recruiting
Study contacts
- Study coordinator: Seismic Contact
- Email: clinical@seismictx.com
- Phone: 1800 244 475
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Pfizer medicine PF-08103402: how different doses are tolerated in healthy adults and adults with mild-to-moderate asthma
This study tests how different amounts of PF-08103402 behave in the body and how well it is tolerated by healthy adults and adults with mild-to-moderate asthma.
-
Comparing how three adhesive dressings stay on the skin
We will test how well three different self-adhesive dressings stick to and stay on the back of healthy adults.
-
Focal muscle vibration to limit leg muscle weakness during reduced use
This trial will see if a 10-day program of focal muscle vibration can limit strength loss in healthy adults whose one leg is temporarily unloaded.
-
Kidney responses to exercise in heat and whether vitamin B3 changes them.
This project will test whether taking vitamin B3 changes how the kidneys respond when healthy, physically fit adults exercise in hot, humid conditions.
-
Assessing the safety of inhaling xenon gas in healthy volunteers
This study is testing if inhaling xenon gas is safe for healthy people to see if it could help in treating neurodegenerative diseases like Alzheimer's in the future.
-
Brain responses to gentle ear stimulation measured with near-infrared light
This one-visit test uses gentle ear stimulation and near-infrared head sensors to see how healthy adults' brains respond.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.